Global Nanopharmaceuticals Overview 2025, Forecast To 2034
19 Mar, 2025
What Fueled The Previous Growth In The Nanopharmaceuticals Market?
The nanopharmaceuticals market has seen considerable growth due to a variety of factors.
• There has been a swift expansion in the size of the nanopharmaceuticals market in the last few years. The market is expected to rise from $95.21 billion in 2024 to $112.49 billion in 2025, marking a compound annual growth rate (CAGR) of 18.2%.
This growth during the historic period can be explained by factors such as the need for efficient treatment methods, rising consciousness about nanopharmaceuticals, the requirement for targeted therapies, an increase in the rate of neurodegenerative diseases, and a growing elderly population.
How Does the Forecast Look for the Nanopharmaceuticals Market?
The nanopharmaceuticals market is expected to maintain its strong growth trajectory in upcoming years.
• The market worth of nanopharmaceuticals is predicted to undergo swift amplification in the ensuing years, and it is projected to expand to $216.39 billion by 2029, registering a compound annual growth rate (CAGR) of 17.8%.
The predicted surge during the forecast period can be linked to the increasing cases of chronic illnesses, escalating Research and Development activities, bolstering healthcare investments, surging demand for tailored medicines, and the rising incidences of cancer. The anticipated period will also see key trends such as the merging of nanotechnology with other cutting-edge technologies, advancements in drug delivery enabled by nanotechnology, progress in biotechnology and genomics sectors, incorporation of Artificial Intelligence, machine learning and computational models, and the overall technological progression.
Gain Insights Into The Nanopharmaceuticals Global Market Report 2025 With A Free Sample Report Here:
What Are The Leading Drivers Of Growth In The Nanopharmaceuticals Market?
The burgeoning occurrence of enduring health problems is set to drive the expansion of the nanopharmaceuticals market in the future. Enduring health problems are persistent issues commonly needing continuous medical care and management across several years or even an individual's entire lifetime, including ailments like cancer, diabetes, cardiovascular diseases, asthma, and others. Such enduring health problems are amplified by factors including unhealthy eating habits, lack of physical exercise, tobacco intake, excessive consumption of alcohol, hereditary factors, and environmental elements. Nanopharmaceuticals are leveraged for enduring health problems by facilitating targeted drug delivery, boosting bioavailability, controlled release, minimized side effects, and advanced combination therapies, thereby enhancing treatment efficiency and patient results. For example, as of April 2022, the National Association of Chronic Disease Directors (NACDD), a non-profit organization based in the US, reported that nearly 60% of adult Americans suffer from at least one enduring health problem, and rough 40% of American adults are grappling with multiple chronic conditions (MCC). This is projected to burden the US economy with a whopping 2 trillion dollars annually, or $8,600 per individual by the year 2030. Consequently, the increasing occurrence of enduring health problems is propelling the growth of the nanopharmaceuticals market.
How Are The Segments Defined Within The Global Nanopharmaceuticals Market?
The nanopharmaceuticalsmarket covered in this report is segmented –
1) By Type: Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Other Product Types
2) By Route Of Administration: Oral, Injectable, Topical, Pulmonary, Other Routes Of Administration
3) By Application: Oncology, Neurology, Anti-inflammatory, Anti-infective, Cardiovascular, Other Applications
4) By End-User: Hospitals And Clinics, Specialty Pharmacies, Research Institutions, Other End Users
Subsegments:
1) By Liposomes: Conventional Liposomes, Pegylated Liposomes, Cationic Liposomes, Anionic Liposomes, Immunoliposomes, Stealth Liposomes, Thermosensitive Liposomes,
2) By Polymeric Micelles: Block Copolymer Micelles, Amphiphilic Polymer Micelles, Biodegradable Polymeric Micelles, Nanoparticle-Polymer Hybrid Micelles, pH-Sensitive Micelles, Thermo-responsive Micelles
3) By Solid Lipid Nanoparticles (SLNs): Conventional SLNs, Nanostructured Lipid Carriers (NLCs), SLNs for Drug Delivery, SLNs for Cosmetic Applications, SLNs with Targeting Ligands, SLNs for Vaccine Delivery
4) By Microemulsion: Oil-in-Water (O/W) Microemulsions, Water-in-Oil (W/O) Microemulsions, Multi-Phase Microemulsions, Microemulsions for Drug Delivery, Microemulsions in Cosmetic Applications, Microemulsions with Active Ingredients
5) By Nanoemulsion: Oil-in-Water (O/W) Nanoemulsions, Water-in-Oil (W/O) Nanoemulsions, Nanoemulsions for Parenteral Administration, Nanoemulsions for Oral Delivery, Nanoemulsions with Enhanced Stability, Nanoemulsions in Food Applications
6) By Other Product Types: Nanocrystals, Dendrimers, Nanocomposites, Nanospheres, Nanotubes, Quantum Dots, Magnetic Nanoparticles
What Trends Are Shaping The Nanopharmaceuticals Market?
Leading firms in the nanopharmaceuticals market are resorting to strategic partnerships to offer critical communication services to individuals, businesses, and government entities. The strategic partnership is a tactic wherein businesses tap into each other's capabilities and resources to attain mutual advantages and success. For example, Nanoform Finland Plc, a nanoparticle medicine corporation based in Finland, entered into a strategic partnership with CBC Co. Ltd., a development-focused trading firm headquartered in Japan, in April 2024. They aimed at uncovering possibilities for Nanoform's advanced nanomedicine engineering technologies. This strategic partnership serves as a pivotal juncture in their quest to use sophisticated nanotechnology to improve medications for patients globally.
Who Are the Key Players In The Nanopharmaceuticals Market?
Major companies operating in the nanopharmaceuticals market are:
• Selecta Biosciences Inc.
• Pfizer Inc.
• Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Sanofi S.A.
• Bristol Myers Squibb Company
• AstraZeneca plc
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Novovax Inc.
• OSI Pharmaceuticals Inc.
• Par Pharmaceutial Inc.
• Samyang Biopharm Corporation
What Is The Most Dominant Region In The Nanopharmaceuticals Market?
North America was the largest region in the global nanopharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.